Autologous Cell Therapy Market Expected to Reach US$ 23.8 Billion in 2024

Cell therapy also termed as cellular therapy in which cellular components is injected into the patient (body) for better treatment outcome and to reduce side effects. A number of cells are used for cellular therapy treatment procedure such as T cells, stem cells, fibroblast, dendritic cells, chondrocyte etc. Autologous cell therapy involves the use of patient’s own cells for the treatment procedure. Rapid technological innovations, high success rate of treatment (less chance of mismatch), and favorable government support boost the market demand for autologous cell therapy market. Unmet medical needs for cell based therapy, and increasing government initiative for cell based research are expected to boost market growth. Cell therapy is considered a promising technique for various disease conditions such as orthopedic, neurological, oncology, and autoimmune diseases. This is because stem cells have the ability to transform into many cell types such as cartilage, bone (osteoblast), tendon, and muscle. Key advantages of autologous cells are cost-effectiveness, quick access to blood (since it is derived from patients only), easy production method, and lowest threat of disease transfusion, thus leading to wide usage.

Download PDF Brochure of Report - http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=715

The autologous cell therapy market by source has been segmented as bone marrow, epidermis and others. The bone marrow segment accounted for major share of the global autologous cell therapy market in 2015. This is because most of the mesenchymal and hematopoietic stem cells are extracted from the bone marrow. High preference and growing demand for bone marrow derived cells are likely to propel the segment in developed regions. The epidermis segment is anticipated to expand at the highest CAGR from 2016 to 2024. This is due to growing preference for stem cells/autosomal cells extracted from the skin as it is the largest organ in the body.

By application the market is categorized into neurology, orthopedic, cancer, wound healing, CVD, autoimmune, and others. The neurology segment accounted for key share of the global autologous cell therapy market in 2015. High preference for cell therapy products for neurodegenerative diseases, rapid rise of stroke death worldwide, and favorable government support accentuates market growth. The cancer segment is expected to expand at a significant CAGR by 2024. This is due to huge product in the pipeline development.

Hospitals, ambulatory centers, and research centers are included into the market by end-user. The hospitals segment accounted for major share of the global autologous cell therapy market in 2015. Most of the cell therapy procedures are performed in the hospitals as patient prefer hospital for cell therapy procedures for effective treatment. This boosts the market demand. The ambulatory centers segment is expected to expand at an outstanding CAGR during the forecast period. This is due to cost-effective treatment as compared to hospitals, shorter waiting time, and rise in number of outpatient surgical procedures.

Major players operating in the global autologous cell therapy market includes BIOTIME, INC., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Vericel Corporation, Pharmicell Co., Inc., TiGenix N.V., Fibrocell Science, Inc. and Opexa Therapeutics, Inc.

Browse Report with Complete TOC - http://www.transparencymarketresearch.com/autologus-cell-therapy-market.html

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.